NCT03480997已完成1 期
A Single Center Study to Measure the Bronchodilator Effect of Albuterol Sulfate or Albuterol Sulfate/Ipratropium Bromide Using the Pneuma Respiratory Inhaler and the ProAir HFA Inhaler in Stable COPD Patients
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Primary Efficacy Endpoint: Change in FEV1
研究概览
简要总结
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product as measured by increases in FEV1.
详细描述
A single center, open label, single dose study to demonstrate the pharmacodynamic bioequivalence of the test and reference metered dose inhalers containing albuterol sulfate or albuterol sulfate/ipratropium in adult patients with COPD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent
- •Diagnosis of COPD as defined by the American Thoracic Society/European Respiratory Society guidelines characterized by progressive airflow limitation associated with abnormal inflammatory response of the lungs to noxious particles or gases primarily caused by cigarette smoking.
- •Have an established COPD clinical history, symptomatic with dyspnea, chronic cough, chronic sputum production or wheezing. At Visit 1, FEV1/FVC ratio must be less than 0.70 or at least 10% less than the FEV1/FVC ratio determined by the predicted normal value. FEV1 must be less than 70% of the predicted normal value and greater than 25% of the predicted normal value.
- •Must be using one or more inhaled bronchodilators for treatment of COPD at the time of Visit
- •Current or former smokers, with a history of at least 10 pack-years of cigarette smoking. Number of pack-years = (number of cigarettes per day/20) X (number of years smoked).
- •Willing, and in the opinion of the investigator, able to adjust current COPD therapy as required by the protocol.
排除标准
- •Current diagnosis of other respiratory disorder(s) including, but not limited to: alpha-1-antitrypsin deficiency; lung cancer; cystic fibrosis; tuberculosis; sarcoidosis; idiopathic pulmonary fibrosis; primary pulmonary hypertension; or pulmonary thromboembolic disease. Patients with concomitant COPD and asthma will be allowed to participate.
- •Diagnosis of non-respiratory disorder(s) that are currently affecting lung function, as determined by he principal investigator including, but not limited to: congestive heart failure; symptomatic cardiac arrhythmia; symptomatic seizure disorder; dementia; lupus; rheumatoid arthritis; or liver cirrhosis.
- •Unable to abstain from protocol defined prohibited medications during the screening and testing period.
- •Unable to withhold short acting bronchodilators for 6 hours prior to spirometry testing at the study visit.
- •Unable to perform acceptable or repeatable spirometry or comply with other study procedures.
- •Known allergic reaction to albuterol sulfate or ipratropium bromide.
- •Diagnosis of cancer that is not presumed to be in remission or cured.
- •Active alcohol or drug abuse.
- •Pregnant or lactating women. Pregnancy confirmed by a positive hCG test.
- •Treatment with another investigational study drug in another clinical study within the last 30 days or five half-lives, whichever is longer.
研究组 & 干预措施
albuterol sulfate and ipratropium bromide
Experimental
albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
干预措施: Albuterol Sulfate and Ipratropium Bromide (Combination Product)
albuterol sulfate 200 mcg
Active Comparator
albuterol sulfate 200 mcg Reference MDI
干预措施: Albuterol Sulfate (Combination Product)
albuterol sulfate 100 mcg
Experimental
albuterol sulfate 100 mcg Test MDI
干预措施: Albuterol Sulfate (Combination Product)
结局指标
主要结局
Primary Efficacy Endpoint: Change in FEV1
时间窗: Just prior to dosing and twenty minutes post dosing
Change in FEV1
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006BronchospasmChronic Obstructive Pulmonary Disease (COPD)AsthmaNCT01189396Amphastar Pharmaceuticals, Inc.27
尚未招募
3 期
Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals LtdMild AsthmaNCT06618105Macleods Pharmaceuticals Ltd144
已完成
1 期
Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg TabletsHealthyNCT01179646Kremers Urban Development Company48
已完成
3 期
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPDPulmonary Disease, Chronic ObstructiveNCT00240435Boehringer Ingelheim491
已完成
2 期
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.Pulmonary Disease, Chronic ObstructiveNCT00528996Boehringer Ingelheim2,080